CN Bio

Executive Summary

CN Bio is a UK-based biotechnology company at the forefront of Organ-on-a-Chip (OOC) technology, addressing a critical bottleneck in drug development: the poor predictability of preclinical models. Its proprietary PhysioMimix platform integrates microfluidic hardware, single-use consumables, and validated human tissue models (e.g., liver, lung, gut) to recapitulate organ-level physiology and function. This enables more accurate assessment of drug efficacy, safety, and metabolism before clinical trials, potentially reducing late-stage failures and animal testing. The company operates a dual revenue model: direct product sales of its platform and consumables to pharmaceutical and biotech firms, and fee-for-service contract research using its assays. Founded in 2009 and headquartered in Cambridge, UK, CN Bio has established itself as a key player in the OOC space, competing with companies like Emulate and Mimetas. While the company remains private and has not disclosed funding rounds or valuation, its technology has been validated through numerous publications and collaborations. The growing regulatory acceptance of OOC data (e.g., FDA modernization efforts) and increasing R&D outsourcing trends provide a favorable tailwind for CN Bio. However, as a smaller private firm, it faces challenges in scaling commercial adoption and competing against larger, better-capitalized peers. Overall, the company is well-positioned to capture value in the transition toward more human-relevant preclinical models.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership for liver-on-a-chip drug metabolism studies70% success
• Q4 2026Regulatory endorsement or guidance from the FDA or EMA supporting OOC data for IND submissions50% success
• Q1 2027Launch of a new multi-organ chip platform (e.g., liver-heart or liver-gut) expanding assay capabilities60% success